Genetic Technologies Ltd. (GENE)
| Market Cap | 18.87M |
| Revenue (ttm) | 4.72M |
| Net Income (ttm) | -4.95M |
| Shares Out | 9.22B |
| EPS (ttm) | -0.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,720 |
| Open | 1.13 |
| Previous Close | 1.15 |
| Day's Range | 1.13 - 1.15 |
| 52-Week Range | 0.95 - 2.85 |
| Beta | 1.09 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 30, 2022 |
About GENE
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as ... [Read more]
Financial Performance
In 2022, GENE's revenue was 6.79 million, an increase of 5,536.33% compared to the previous year's 120,554. Losses were -7.13 million, 0.75% more than in 2021.
Financial numbers in AUD Financial StatementsNews
Genetic Technologies Announces Q1 FY23 Quarterly Results and Investor Webinar Details
MELBOURNE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, welln...
Genetic Technologies Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
ORLANDO, FL / ACCESSWIRE / October 13, 2022 / RedChip Companies will air a new interview with Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) ("Company", "GTG"), a global leader in genomics-based te...
Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for br...
MELBOURNE, Australia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious ...
Genetic Technologies Provides Update on US Operations and Payer Engagement
MELBOURNE, Australia, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”, “GENE”), a global leader in guideline driven genomics-based tests in heal...
GENE Momentum building - a year in review
MELBOURNE, Australia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in guideline driven genomics-based tests in health, well...
Gene achieves key milestones and growth
MELBOURNE, Australia, July 28, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious ...
Completion of AffinityDNA Acquisition expanding global direct-to-consumer business
MELBOURNE, Australia, July 14, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious ...
GeneType Risk Assessment Test onboarding in 16 clinics
MELBOURNE, Australia, July 01, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious ...
Acquisition of global direct to consumer ecommerce business
MELBOURNE, Australia, May 16, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious d...
Genetic Technologies drives leadership in precision medicine with Multi-Risk Test
MELBOURNE, Australia, April 08, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, ASX: GTG) (“GENE” or the “Company”), a global leader in genomics-based tests in health, wellness and ...
Genetic Technologies Reports Q2 FY22 Cash Flow Results
Q2 momentum sets the stage for a strong FY22 Q2 momentum sets the stage for a strong FY22
GENE Presents Study Involving 200,000 Participants at 2021 San Antonio Breast Cancer Symposium
MELBOURNE, Australia, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious ...
Genetic Technologies Announces New Partnership and geneType COVID-19 Risk Test Patent Allowance from the USPTO
MELBOURNE, Australia, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious ...
Genetic Technologies Reports Q1 FY22 Results
Genetype MultiTest submitted for regulatory approval as commercialization plans gather momentum increase in cash receipts over prior quarter Genetype MultiTest submitted for regulatory approval as comme...
GENE Embarks on Breakthrough African American Collaboration for Breast Cancer as Part of Its Commitment to Ethnic Div...
Study to focus on women of African American descent for expanded polygenic risk test Study to focus on women of African American descent for expanded polygenic risk test
BelHealth Completes Asset Sale of General Genetics Corp.
FORT LAUDERDALE, Fla., Sept. 9, 2021 /PRNewswire/ -- September 9, 2021–BelHealth Investment Partners, LLC ("BelHealth") is pleased to announce that it has completed the sale of assets of the internation...
Genetic Technologies Reports FY21 Results as it Turns the Corner on its Commercialization Strategy
Company to present at H.C. Wainwright 23rd Annual Global Investment Conference taking place virtually September 13-15, 2021 Company to present at H.C. Wainwright 23rd Annual Global Investment Conference...
Genetic Technologies Rapidly Accelerating Commercialization Plans
MELBOURNE, Australia, July 26, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”, “GTG”), a global leader in Genomics based tests in health, wellness and serious disease, is...
Genetic Technologies Acquires EasyDNA To Expand Into Wellness Testing
Genetic Technologies Limited (NASDAQ: GENE) has agreed to acquire EasyDNA's brand and distribution rights from BelHealth for $4 million in cash and stock. EasyDNA currently sells paternity, oncology, an...
Genetic Technologies Strengthens Global Leadership in Genomics with Acquisition of EasyDNA
A global platform to market the Company's portfolio across 40 countries A global platform to market the Company's portfolio across 40 countries
Genetic Technologies Continues to Break New Ground as it Advances Development of its Predictive Risk Test for Multipl...
MELBOURNE, Australia, July 09, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG, NASDAQ: GENE, "Company", "GTG"), a diversified Genomics and AI driven preventative health business, today ...
US Patent Office Grants Foundational Pharmacogenomic Patent
MELBOURNE, Australia, June 11, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business, has be...
Infinity BiologiX, Genetic Technologies and Vault Heath launch new test to assess severity of COVID-19 in individuals
PISCATAWAY, N.J.--(BUSINESS WIRE)-- #covid19--Today, Infinity BiologiX (IBX) announces the launch of a new test meant to assess the severity of COVID-19 in individuals. The COVID-19 Risk Test is designe...
Genetic Technologies Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
MELBOURNE, Australia, May 13, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business, today a...
Genetic Technologies appoints Mike Tonroe as CFO
MELBOURNE, Australia, April 12, 2021 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), announces the appointment of Michael Tonroe to th...